



REPORT NUMBER 58  
Issued September 2003

CENTERS FOR DISEASE CONTROL AND PREVENTION

# HEPATITIS

## SURVEILLANCE



## **Suggested Citation**

Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 58. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2003

The report is also available by Internet at: [www.cdc.gov/hepatitis](http://www.cdc.gov/hepatitis)

## **Preface**

Hepatitis Surveillance, No. 58 presents statistics and trends in viral hepatitis in the United States through 2001. This publication, which summarizes viral hepatitis case reports received from state health departments, is intended as a reference document for policy makers, program managers, health planners, researchers and others who are concerned with the public health implications of these diseases. Any comments and suggestions that would improve the usefulness of future publications are appreciated and should be sent to Chief, Surveillance Team, Division of Viral Hepatitis, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop G37, Atlanta, GA 30333.

## **Acknowledgments**

Publication of this report would not have been possible without the contributions of the State and Territorial Health Departments that provide state and local surveillance data to the Centers for Disease Control and Prevention.

This report was prepared by the following staff members of the Surveillance Team of the Epidemiology Branch of the Division of Viral Hepatitis, National Center for Infectious Diseases: Annemarie Wasley, Steven Bloom, and Lyn Finelli.

## **Contents**

List of Figures .....	ii
List of Tables .....	iii
Methods .....	1
Acute Hepatitis A, 2001 .....	11
Acute Hepatitis B, 2001 .....	25
Acute Hepatitis C/NANB Hepatitis, 2001 .....	39
Future Directions.....	51
Appendices .....	53
References .....	57

## List of Figures

Figure 1:	Geographic Divisions of the United States . . . . .	4
Figure 2:	Incidence of reported viral hepatitis, United States, 1966-2001 . . . . .	5
Figure 3:	Incidence of Hepatitis A, 1966-2001 . . . . .	13
Figure 4:	Incidence of Hepatitis A, by Region, 1975-2001 . . . . .	14
Figure 5:	Incidence of Hepatitis A, by County, 2001 . . . . .	15
Figure 6:	Incidence of Hepatitis A, by Age, 1990-2001 . . . . .	16
Figure 7:	Incidence of Hepatitis A, by Sex, 1990-2001 . . . . .	17
Figure 8:	Incidence of Hepatitis A, by Age and Sex, 2001 . . . . .	18
Figure 9:	Incidence of Hepatitis A, by Race and Ethnicity, 1990-2001 . . . . .	19
Figure 10:	Trends in Selected Epidemiologic Characteristics among Patients with Hepatitis A, by Year, 1996-2001 . . . . .	22
Figure 11:	Incidence of Acute Hepatitis B, 1966-2001 . . . . .	27
Figure 12:	Incidence of Acute Hepatitis B, by Region, 1975-2001 . . . . .	28
Figure 13:	Incidence of Acute Hepatitis B, by County, 2001 . . . . .	29
Figure 14:	Incidence of Acute Hepatitis B, by Age, 1990-2001 . . . . .	30
Figure 15:	Incidence of Acute Hepatitis B, by Sex, 1990-2001 . . . . .	31
Figure 16:	Incidence of Acute Hepatitis B, by Age and Sex, 2001 . . . . .	32
Figure 17:	Incidence of Acute Hepatitis B, by Race and Ethnicity, 1990-2001 . . . . .	33
Figure 18:	Trends in Selected Epidemiologic Characteristics among Patients with Acute Hepatitis B, by Year . . . . .	36
Figure 19:	Incidence of Acute Hepatitis C/NANB, 1982-2001 . . . . .	41
Figure 20:	Incidence of Acute Hepatitis C/NANB, by Age, 1992-2001 . . . . .	42
Figure 21:	Incidence of Acute Hepatitis C/NANB, by Sex, 1992-2001 . . . . .	43
Figure 22:	Incidence of Acute Hepatitis C/NANB, by Age and Sex, 2001 . . . . .	44
Figure 23:	Incidence of Reported Acute Hepatitis C/NANB, by Race and Ethnicity, 2001 . . . . .	45
Figure 24:	Trends in Selected Epidemiologic Characteristics among Patients Reported with Acute Hepatitis C/NANB, by Year . . . . .	48

## List of Tables

Table 1:	Proportion of Reported Cases That Included Risk Factor Data, by State, 2001.....	2
Table 2:	Reported cases of acute viral hepatitis, by type and year, United States, 1966-2001 .....	6
Table 3:	Reported cases of acute viral hepatitis, by type, state and year, 1990-2001 .....	7
Table 4:	Epidemiologic Characteristics of Patients Reported with Hepatitis A, by Age, 2001 (Crude frequency) .....	20
Table 5:	Epidemiologic Characteristics of Patients Reported with Hepatitis A, by Age, 2001 (Mutually exclusive categories) .....	21
Table 6:	Clinical Characteristics of Patients Reported with Hepatitis A, By Age, 2001 .....	23
Table 7:	Epidemiologic Characteristics of Patients Reported with Acute Hepatitis B, by Age, 2001 (Crude frequency) .....	34
Table 8:	Epidemiologic Characteristics of Patients Reported with Acute Hepatitis B, by Age, 2001 (Mutually exclusive categories) ....	35
Table 9:	Clinical Characteristics of Patients Reported with Acute Hepatitis B, by Age, 2001 .....	37
Table 10:	Epidemiologic Characteristics of Patients Reported with Acute Hepatitis C/NANB, by Age, 2001 (Crude Frequency) .....	46
Table 11:	Epidemiologic Characteristics of Patients Reported with Acute Hepatitis C/NANB by Age, 2001 (Mutually exclusive categories) ..	47
Table 12:	Clinical Characteristics of Patients with Acute Hepatitis C/NANB, by Age, 2001.....	49

*Page intentionally left blank*

## Methods

### Conditions under surveillance

National surveillance is conducted for acute hepatitis A, acute hepatitis B, acute hepatitis C and acute non-A, non-B hepatitis (NANB). Case definitions for these conditions are below. Nationwide reporting of perinatal HBV infection was implemented in 2001. In addition, chronic hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, past or present were added to the list of nationally notifiable conditions in January 2003. This publication summarizes information received about reported cases of acute disease.

### Sources of data

Cases of acute hepatitis are reported to CDC by state and territorial health departments on a weekly basis via the National Notifiable Diseases Surveillance System (NNDSS). As of January 1, 2002, all reports are received electronically by CDC via NETSS (National Electronic Telecommunications System for Surveillance). However, for the period covered by this report, states could report data using hard-copy forms or by electronic means. The data used in this report are based on a combination of aggregated NETSS data and summary hardcopy reports received for the years 1990 through 2001.

Participation by states in the reporting of viral hepatitis cases to CDC is voluntary as it is for all nationally notifiable diseases. Currently, all states collect and report basic information (event date, source of report, demographic characteristics) about cases of acute viral hepatitis that are identified in their states. States are also asked to report additional information (laboratory test results, clinical information and exposure history) about investigated cases. Completeness of reporting of these additional data varies among and within states. Currently, approximately 30% of case reports received by CDC include extended data. See Table 1 for information on state-specific reporting profiles.

### Analyses

#### *Incidence rate calculations*

Crude incidence rates of new cases were calculated on an annual basis per 100,000 population using Bureau of the Census estimates of the U.S. resident population.

#### *Frequency analysis*

Analyses of risk factors and clinical characteristics were based on case reports that included information on symptoms and serologic test results to verify the presence of acute viral hepatitis. For individuals who report more than one risk factor, the assignment of a source of infection is based on a hierarchy of mutually exclusive categories that represents the relative efficiency of transmission by various routes. For example, based on the hierarchy used for hepatitis B risk factors, a case in which the individual's reported exposures during the incubation period included injecting illegal

drugs and having had multiple sex partners would be attributed to injection drug use. In the tables summarizing the analysis of mutually exclusive risk factors, the risk factors are listed according to their order in the hierarchy specific for that disease. For comparison, the crude frequencies of reported risk factors are included in separate tables.

**Table 1: Proportion of Reported Cases That Included Risk Factor Data, by State, 2001**

81%-100%	61% - 80%	41-60%	11-40%	0-10%
Alabama	Delaware	Colorado	Arizona	Arkansas
D.C.	Illinois	Connecticut	Florida	California
Hawaii	Maine	Michigan	Georgia	Idaho
Indiana	Massachusetts	Missouri	Louisiana	Mississippi
Iowa	Montana	Nebraska	New Mexico	New Hampshire
Kansas	New York	Pennsylvania	South Carolina	New Jersey
Maryland	North Dakota	Virginia		New York City
Minnesota	Ohio	Wyoming		Oregon
Nevada	Oklahoma			Texas
North Carolina	Tennessee			
Rhode Island	Utah			
South Dakota				
Vermont				
Washington				
West Virginia				
Wisconsin				

## Data Limitations

There is considerable variability by state in terms of both the sensitivity of reporting (i.e. frequency of underreporting) and the completeness of individual case reports. Information to assess the degree of underreporting is not available. Only 30% of cases are reported with extended case investigation data (e.g., clinical characteristics, exposure history) and this percentage varies by state from 0 to 100% (see Table 1). Analyses of trends in the characteristics of reported cases are based on records for which this information is complete; it is not known if or how cases that are reported with complete data differ from those for which data are missing or from those that are not reported.

As a result of widespread use of laboratory testing and implementation of laboratory reporting requirements, an increasing number of reports are being made to health departments on the basis of a laboratory test result alone. For many of these cases, information about symptoms or additional serologic testing is not available to distinguish case reports that are likely to represent cases of acute hepatitis from those representing chronic infection (in the case of infection with HBV or HCV), previous infections or false positive test results. To minimize the effect of including misclassified cases on assessments of epidemiologic trends, analysis of clinical characteristics and risk factors were restricted to those reports that included sufficient information to verify that the cases meet the definition for acute disease.



## Case definitions

Reported cases must meet the clinical criteria and be serologically confirmed.

### *Clinical case definition*

An acute illness with a) discrete onset of symptoms and b) jaundice or elevated serum aminotransferase levels

### *Laboratory criteria for diagnosis*

◆ *Hepatitis A:*

- Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive

◆ *Hepatitis B:*

- IgM antibody to hepatitis B core antigen (anti-HBc) positive or hepatitis B surface antigen (HBsAg) positive
- IgM anti-HAV negative (if done)

◆ *Hepatitis C:*

- Serum alanine aminotransferase levels greater than 7 times the upper limit of normal, and
- IgM anti-HAV negative, and
- IgM anti-HBc negative (if done) or HBsAg negative, and
- Antibody to hepatitis C virus (anti-HCV) positive, verified by an additional more specific assay


◆ *Non-A, Non-B hepatitis:*

- Serum aminotransferase levels greater than 2.5 times the upper limit of normal, and
- IgM anti-HAV negative, and
- IgM anti-HBc negative (if done) or HBsAg negative, and
- Anti-HCV negative (if done)

## Case classification

Confirmed: a case that meets the clinical case definition and is laboratory confirmed or, for hepatitis A, a case that meets the clinical case definition and occurs in a person who has an epidemiologic link with a person who has laboratory-confirmed hepatitis A (i.e., household or sexual contact with an infected person during the 15-50 days before the onset of symptoms)

Figure 1. Geographic Divisions of the United States



West	Midwest	South	Northeast
Alaska	Illinois	Alabama	Connecticut
Arizona	Indiana	Arkansas	Maine
California	Iowa	Delaware	Massachusetts
Colorado	Kansas	District of Columbia	New Hampshire
Hawaii	Michigan	Florida	New Jersey
Idaho	Minnesota	Georgia	New York
Montana	Missouri	Kentucky	Pennsylvania
Nevada	Nebraska	Louisiana	Rhode Island
New Mexico	North Dakota	Maryland	Vermont
Oregon	Ohio	Mississippi	
Utah	South Dakota	North Carolina	
Washington	Wisconsin	Oklahoma	
Wyoming		South Carolina	
		Tennessee	
		Texas	
		Virginia	
		West Virginia	

**Figure 2: Incidence of reported viral hepatitis,  
United States, 1966-2001**




Table 2: Reported cases of acute viral hepatitis, by type and year,  
United States, 1966-2001

Year	Hepatitis A		Hepatitis B		Hepatitis C/NANB	
	No.	Rate**	No.	Rate	No.	Rate
1966	32,859	16.77	1,497	0.79	***	***
1967	38,909	19.67	2,458	1.28	***	***
1968	45,893	22.96	4,829	2.49	***	***
1969	48,416	23.98	5,909	3.02	***	***
1970	56,797	27.87	8,310	4.08	***	***
1971	59,606	28.90	9,556	4.74	***	***
1972	54,074	25.97	9,402	4.52	***	***
1973	50,749	24.18	8,451	4.03	***	***
1974	40,358	19.54	10,631	5.15	***	***
1975	35,855	16.82	13,121	6.30	***	***
1976	33,288	15.51	14,973	7.14	***	***
1977	31,153	14.40	16,831	7.78	***	***
1978	29,500	13.53	15,016	6.89	***	***
1979	30,407	13.82	15,452	7.02	***	***
1980	29,087	12.84	19,015	8.39	***	***
1981	25,802	11.25	21,152	9.22	***	***
1982	23,403	10.11	22,177	9.58	2,629*	1.14
1983	21,532	9.20	24,318	10.39	3,470*	1.48
1984	22,040	9.33	26,115	11.06	3,871*	1.64
1985 <sup>†</sup>	23,257	10.04	26,654	11.51	4,192*	1.81
1986 <sup>†</sup>	23,430	10.02	26,107	11.17	3,634*	1.55
1987	25,280	10.39	25,916	10.65	2,999*	1.23
1988	28,507	11.59	23,177	9.42	2,619*	1.07
1989	35,821	14.43	23,419	9.43	2,529*	1.02
1990	31,441	12.64	21,102	8.48	2,553*	1.03
1991	24,378	9.67	18,003	7.14	3,582*	1.42
1992	23,112	9.06	16,126	6.32	6,010	2.36
1993	24,238	9.39	13,361	5.18	4,786	1.86
1994	26,796	10.29	12,517	4.81	4,470	1.78
1995	31,582	12.02	10,805	4.11	4,576	1.74
1996	31,032	11.70	10,637	4.01	3,716	1.40
1997	30,021	11.21	10,416	3.90	3,816	1.43
1998	23,229	8.60	10,258	3.80	3,518	1.30
1999	17,047	6.25	7,694	2.82	3,111	1.14
2000	13,397	4.75	8,036	2.85	3,197	1.13
2001	10,615	3.77	7,844	2.79	1,640 <sup>††</sup>	0.61

Source: National Notifiable Diseases Surveillance System

\*Numbers and rates shown for hepatitis C/ Non-A, non-B hepatitis are unreliable.

\*\*Rate per 100,000 population.

\*\*\*Not reported until 1982.

<sup>†</sup>Excludes cases from New York City; data not available for 1985 or 1986.

<sup>††</sup>Excludes cases from New Jersey and Missouri.

**Table 3: Reported cases of acute viral hepatitis,  
by type, state and year, United States, 1990-2001**

Hepatitis A (cases per 100,000 persons)												
	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	2.4	1.1	1.3	1.4	3.3	2.2	5.1	2.0	1.9	1.4	1.3	1.8
Alaska	34.4	16.9	22.2	129.8	34.8	8.3	8.9	5.6	2.8	2.4	2.1	2.6
Arizona	53.8	29.7	31.7	37.4	52.1	31.6	39.9	51.2	39.5	14.6	9.1	8.0
Arkansas	25.7	10.9	6.5	3.1	10.3	26.7	20.0	8.8	3.2	3.2	5.4	2.8
California	21.4	16.5	16.0	18.2	21.1	21.5	20.9	20.0	12.8	10.4	8.8	5.5
Colorado	10.7	20.2	25.5	24.6	16.0	13.6	13.4	10.3	8.7	5.4	5.2	2.1
Connecticut	4.2	3.8	2.5	3.6	3.0	2.6	4.3	4.6	3.0	3.9	5.2	7.0
Delaware	14.3	1.9	8.1	1.7	3.1	1.7	2.9	4.2	0.8	0.3	1.9	2.0
District of Columbia	6.5	13.0	2.9	1.9	4.8	4.7	7.2	6.8	12.6	11.4	7.0	14.0
Florida	5.2	6.4	4.3	5.1	5.6	4.7	5.1	5.5	4.1	5.7	4.1	5.3
Georgia	5.8	3.7	3.4	2.1	0.6	1.2	5.6	10.2	11.5	6.2	4.6	11.4
Hawaii	9.5	7.9	14.9	5.9	4.9	14.0	10.1	12.4	4.5	2.0	1.1	1.4
Idaho	9.5	9.5	12.8	27.1	33.5	30.3	20.8	12.4	19.1	3.8	3.5	4.4
Illinois	15.1	12.2	6.7	8.7	5.2	5.6	6.4	7.2	6.8	7.0	5.6	3.6
Indiana	4.6	8.9	14.1	11.3	6.3	3.3	6.3	5.6	2.9	1.8	2.2	1.7
Iowa	10.1	1.7	1.9	2.1	2.3	3.8	11.7	17.2	14.0	5.6	2.3	1.2
Kansas	10.9	3.6	5.6	3.1	4.3	6.3	15.2	10.1	4.1	2.5	4.1	6.7
Kentucky	2.5	1.9	3.7	3.7	5.8	1.1	1.4	2.0	0.8	1.7	1.6	3.6
Louisiana	5.3	3.5	5.5	2.5	3.9	4.5	6.0	6.1	4.0	4.9	2.4	1.9
Maine	0.9	1.7	2.3	1.1	2.0	2.4	2.3	5.3	1.6	2.2	1.7	0.9
Maryland	19.8	5.6	5.2	3.2	4.0	4.4	5.1	3.7	8.1	5.9	4.0	5.6
Massachusetts	6.6	4.8	4.9	3.5	1.9	2.7	3.8	4.2	2.0	2.3	2.2	5.9
Michigan	4.1	3.1	1.6	2.2	3.7	3.8	5.2	14.0	21.7	12.7	4.9	3.3
Minnesota	7.4	10.9	19.8	11.0	5.7	4.3	3.8	5.2	3.1	2.7	3.8	1.0
Mississippi	1.8	1.3	1.6	2.3	2.9	8.3	8.3	3.5	2.5	4.6	5.0	1.3
Missouri	12.1	12.7	28.9	27.5	11.7	25.1	26.3	21.3	11.7	13.0	4.6	1.6
Montana	19.9	10.2	10.6	9.2	2.9	19.9	14.8	8.1	10.9	2.0	0.8	1.8
Nebraska	6.6	15.5	16.6	12.1	7.5	4.0	9.5	6.8	1.6	3.2	2.2	2.2
Nevada	26.3	24.2	8.3	12.6	17.4	21.9	28.0	26.0	13.0	8.1	4.5	3.5
New Hampshire	0.8	2.7	2.9	1.6	1.5	1.1	1.9	3.0	1.6	1.5	1.5	1.5
New Jersey	5.6	4.2	4.0	3.7	3.9	3.9	4.9	3.9	4.2	1.9	3.4	3.4
New Mexico	71.1	44.7	21.7	24.8	66.5	48.0	20.8	20.4	8.9	3.2	3.8	2.2
New York	11.9	8.4	3.3	4.3	5.0	4.8	4.1	3.7	3.5	2.7	2.4	3.0
New York City	10.8	13.9	12.1	9.9	12.8	13.7	8.3	12.3	8.0	5.4	6.6	5.6
North Carolina	9.7	2.4	1.6	1.4	2.1	1.5	2.8	2.8	1.7	2.2	1.9	3.0
North Dakota	5.2	10.4	22.5	12.6	0.9	3.6	21.8	2.2	0.6	0.5	0.6	0.5
Ohio	2.7	3.3	4.1	3.1	10.8	15.8	7.0	3.0	3.6	5.8	2.4	2.3
Oklahoma	19.3	9.0	6.8	6.6	12.9	43.6	78.5	43.5	19.9	15.9	7.9	3.4
Oregon	29.0	15.3	18.5	17.5	40.2	86.7	27.4	11.6	13.3	7.6	5.0	3.1
Pennsylvania	15.0	3.6	2.1	1.5	1.8	2.1	4.5	4.2	3.5	3.0	3.6	2.5
Rhode Island	5.2	11.4	17.0	7.7	3.0	3.5	2.6	13.3	1.8	3.5	3.0	7.2
South Carolina	1.3	1.2	0.6	0.5	1.1	1.2	1.5	2.9	1.4	1.2	2.4	2.1
South Dakota	70.8	118.3	30.1	2.5	5.3	13.5	5.8	3.7	5.4	1.4	0.4	0.4
Tennessee	4.4	3.2	2.3	2.0	6.7	37.3	14.7	7.8	4.3	2.7	2.7	3.3
Texas	16.0	15.4	10.3	15.5	15.7	16.1	18.2	23.3	17.9	12.6	9.3	2.6
Utah	35.3	16.2	38.2	44.2	38.8	34.9	53.1	26.6	9.3	3.0	3.2	3.0
Vermont	1.1	4.2	2.5	1.6	2.4	1.4	2.0	2.5	2.9	4.0	1.6	2.6
Virginia	4.9	3.0	2.6	2.4	3.0	3.6	3.3	3.7	3.3	2.7	2.3	2.4
Washington	28.1	12.1	16.8	17.6	21.0	17.2	18.1	18.1	18.2	8.8	5.1	3.1
West Virginia	1.3	1.2	0.6	1.6	1.3	1.3	1.0	0.7	0.5	2.6	3.1	1.6
Wisconsin	9.8	15.8	18.7	10.0	4.8	3.6	3.8	3.6	3.6	1.5	2.0	1.6
Wyoming	16.1	29.5	3.0	3.6	8.6	23.0	8.5	7.3	7.7	1.9	0.8	1.4

**Table 3: Reported cases of acute viral hepatitis,  
by type, state and year, United States, 1990-2001 (Continued)**

Hepatitis B (cases per 100,000 persons)												
	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	4.1	4.2	3.3	2.6	2.1	2.7	1.8	1.9	1.7	2.0	1.6	2.0
Alaska	10.5	7.2	3.6	2.5	2.2	2.2	2.6	2.5	2.1	2.9	2.1	1.6
Arizona	13.2	4.7	5.1	2.4	2.5	2.8	5.3	4.4	4.0	2.9	4.2	3.2
Arkansas	5.2	6.5	4.5	3.7	2.4	3.3	3.7	4.2	4.5	3.8	4.1	4.0
California	9.8	8.6	9.2	6.0	6.5	5.5	5.4	5.1	4.4	3.7	3.2	2.5
Colorado	5.9	4.2	3.5	2.3	2.7	3.7	3.5	3.8	2.6	2.4	2.5	2.4
Connecticut	7.8	5.9	4.9	2.3	2.9	2.6	2.5	1.7	1.2	1.2	1.4	1.4
Delaware	14.6	7.9	30.3	2.6	2.0	1.3	1.2	1.0	0.5	0.1	1.9	3.7
District of Columbia	21.4	26.4	14.5	7.5	9.4	3.8	5.9	5.7	3.6	4.8	6.1	2.3
Florida	7.4	7.2	6.9	6.2	5.4	4.7	4.6	4.4	3.5	3.9	3.9	3.2
Georgia	8.3	8.9	4.7	9.7	7.9	1.4	0.8	3.0	2.7	3.0	4.3	5.3
Hawaii	9.5	4.4	1.6	1.9	2.4	2.7	1.2	0.9	1.5	1.3	1.0	1.8
Idaho	9.1	7.0	7.9	8.1	6.8	8.8	7.4	4.5	4.0	2.3	0.8	0.9
Illinois	5.2	3.6	3.4	2.9	2.7	2.5	2.8	2.4	1.9	1.7	1.4	1.8
Indiana	6.6	4.2	4.0	4.4	3.7	4.2	2.5	1.7	2.0	1.3	1.4	1.2
Iowa	1.9	1.5	1.2	1.3	1.0	1.6	2.6	1.5	1.9	1.5	1.3	0.8
Kansas	5.6	2.4	2.6	2.6	1.2	2.1	1.2	1.2	1.1	0.6	1.0	0.5
Kentucky	12.6	5.2	2.9	2.6	2.0	1.8	2.0	1.1	1.2	1.3	2.0	1.6
Louisiana	8.9	9.1	6.1	6.3	4.7	5.6	4.8	4.8	5.0	3.9	3.5	2.8
Maine	2.4	2.6	2.2	0.9	0.9	1.0	0.6	0.5	0.4	0.2	0.4	0.5
Maryland	11.8	8.0	8.2	5.4	7.1	5.2	3.3	3.4	2.8	2.9	2.5	2.7
Massachusetts	10.7	9.1	6.4	3.6	3.3	1.9	1.8	1.3	1.3	0.7	0.2	0.6
Michigan	6.9	6.5	6.2	4.1	4.5	4.1	4.3	4.7	4.8	5.2	4.3	6.2
Minnesota	2.8	2.3	2.1	2.1	1.8	2.0	2.0	1.3	1.5	1.7	1.2	0.9
Mississippi	4.8	2.9	13.1	14.8	.	.	9.0	6.6	3.4	4.7	3.9	3.3
Missouri	12.3	10.6	10.3	11.2	10.2	8.2	6.1	6.7	4.6	4.2	2.7	2.3
Montana	9.4	8.7	4.9	3.3	2.5	2.8	2.4	1.4	0.9	2.4	0.9	0.3
Nebraska	2.1	2.5	2.8	1.2	1.9	2.4	2.4	1.6	1.4	1.3	2.6	2.0
Nevada	24.3	15.0	8.0	5.4	4.0	4.3	5.9	4.8	4.6	3.3	2.8	2.6
New Hampshire	3.7	3.0	4.5	2.4	2.5	2.0	1.8	1.5	1.8	1.4	1.5	1.3
New Jersey	7.0	6.3	6.5	5.2	5.2	4.6	3.5	3.1	2.5	1.7	2.1	3.4
New Mexico	15.5	13.3	13.2	13.3	13.2	19.1	24.4	14.9	17.9	12.4	7.9	7.5
New York	6.5	5.5	4.8	4.2	3.7	3.8	3.3	3.4	2.4	1.9	1.4	1.4
New York City	9.2	5.0	6.0	4.8	7.4	7.1	6.7	6.2	5.7	3.9	6.9	8.2
North Carolina	16.4	8.3	6.3	4.5	4.1	4.3	4.6	3.6	3.2	2.9	3.2	2.7
North Dakota	1.3	0.3	0.6	0.2	0.2	0.8	0.3	1.1	0.6	0.3	0.5	0.3
Ohio	3.6	3.7	2.1	1.7	1.5	1.0	1.1	0.8	0.7	0.8	0.9	0.8
Oklahoma	5.8	6.5	5.9	6.0	4.3	5.3	1.7	2.0	5.1	5.5	5.2	3.4
Oregon	14.7	10.6	10.3	7.3	5.1	4.1	4.0	3.7	6.1	3.5	3.6	4.9
Pennsylvania	6.2	4.2	4.1	3.0	3.4	2.4	2.4	2.9	3.0	2.4	2.2	2.7
Rhode Island	5.3	2.8	2.0	1.9	0.8	1.0	1.9	2.2	7.6	4.3	4.4	3.1
South Carolina	17.8	18.7	1.5	1.4	0.9	1.5	2.7	2.6	1.7	1.6	0.6	1.8
South Dakota	1.1	1.3	0.7	.	0.5	0.3	0.7	0.1	0.5	0.1	0.3	0.1
Tennessee	17.7	19.1	21.0	22.7	20.2	12.4	9.7	8.5	5.4	3.8	4.2	4.8
Texas	10.5	11.3	8.7	7.5	7.8	6.5	6.6	6.4	9.9	4.3	5.1	3.4
Utah	6.4	2.5	1.6	3.7	4.9	3.8	6.4	4.5	3.1	1.8	1.7	1.1
Vermont	9.0	3.4	3.0	1.7	2.1	1.2	2.4	1.9	1.7	0.8	1.0	0.8
Virginia	4.5	3.5	3.0	2.4	2.2	1.8	2.4	2.0	1.6	1.5	2.5	3.0
Washington	12.6	9.4	7.7	4.7	4.8	4.2	2.9	2.0	2.4	1.9	2.2	2.9
West Virginia	4.9	3.6	3.0	2.4	2.6	2.9	2.0	0.9	0.8	1.6	1.7	1.9
Wisconsin	9.1	9.7	9.6	6.3	1.9	1.6	1.7	10.9	9.8	0.6	0.8	0.9
Wyoming	5.1	7.2	4.7	7.2	5.1	6.9	9.4	5.2	2.3	2.9	0.6	0.6

**Table 3: Reported cases of acute viral hepatitis,  
by type, state and year, United States, 1990-2001 (Continued)**

Hepatitis C/NANB (cases per 100,000 persons)												
	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	0.6	0.6	0.4	0.1	0.5	0.1	0.2	0.3	0.1	0.0	0.2	0.1
Alaska	1.6	2.3	1.2	2.0	.	0.5	0.5	.	.	.	.	.
Arizona	2.0	0.5	0.9	0.3	0.7	1.4	1.7	0.6	0.4	1.0	0.4	0.2
Arkansas	0.8	0.2	0.2	0.2	0.3	0.3	0.3	0.6	1.2	1.2	0.4	0.6
California	2.1	1.3	3.4	1.8	1.8	1.6	1.5	2.7	2.6	0.6	0.3	0.3
Colorado	1.6	2.7	2.9	1.7	2.2	1.8	1.7	1.0	0.8	0.9	0.4	0.3
Connecticut	0.3	0.1	.	.	.	.	.	.	.	.	.	.
Delaware	1.3	0.7	29.6	0.1	0.3	.	0.1	.	.	.	0.3	1.4
District of Columbia	1.3	40.8	47.5	0.5	0.4	.	.	.	.	0.2	0.5	.
Florida	0.6	0.7	1.4	0.3	0.7	0.9	0.9	1.0	0.7	0.5	0.3	0.4
Georgia	0.2	1.5	2.0	6.5	3.1	0.4	.	.	0.1	0.1	0.0	.
Hawaii	1.7	1.6	14.8	0.3	0.4	10.5	18.3	15.3	4.5	.	0.2	.
Idaho	0.8	0.6	.	.	6.3	5.0	8.3	7.1	7.1	0.6	0.2	0.2
Illinois	0.7	0.9	1.0	0.9	0.7	0.7	0.8	0.7	0.3	0.4	0.2	0.1
Indiana	0.6	5.7	0.5	0.3	0.2	0.2	0.1	0.2	0.1	0.1	.	0.0
Iowa	0.5	0.4	0.2	0.3	0.5	0.5	1.9	1.0	0.3	.	0.1	.
Kansas	1.6	0.8	0.6	0.7	0.7	0.7	0.6	0.5	0.2	.	0.3	0.3
Kentucky	1.1	0.2	0.2	0.4	0.8	0.9	0.7	0.4	0.6	0.7	1.0	0.3
Louisiana	0.1	2.4	3.0	4.2	5.0	5.1	6.7	6.3	3.1	6.9	10.2	3.4
Maine	0.4	0.4	0.5	0.2	.	.	.	.	.	0.2	0.2	0.1
Maryland	0.9	1.0	0.7	0.8	0.4	0.1	0.1	0.2	0.4	0.4	0.3	0.2
Massachusetts	0.4	0.5	0.9	1.3	2.0	1.7	1.2	0.8	0.8	0.1	0.3	0.4
Michigan	0.5	1.5	5.1	4.2	2.1	2.5	3.6	4.0	4.8	8.3	2.0	1.4
Minnesota	0.8	0.4	0.6	0.3	0.4	0.1	0.2	0.1	0.4	0.5	0.3	0.7
Mississippi	0.6	0.4	0.0	0.4	.	.	5.6	4.1	3.0	7.1	10.7	3.9
Missouri	0.8	0.7	0.5	0.5	0.6	0.4	0.4	0.2	0.3	5.8	10.8	20.0
Montana	0.9	4.1	3.4	0.4	1.5	2.1	2.3	2.7	0.9	0.6	0.6	0.1
Nebraska	0.3	0.1	5.6	0.7	0.9	1.4	0.5	0.2	0.3	0.2	0.3	0.6
Nevada	2.6	2.4	1.1	1.4	1.4	1.7	1.3	1.1	1.1	0.6	0.9	0.6
New Hampshire	0.8	0.8	2.2	0.7	1.0	1.2	0.6	.	.	.	.	.
New Jersey	0.6	1.4	1.2	1.2	2.7	2.4	.	.	.	.	6.7	14.5
New Mexico	1.8	1.6	3.4	6.6	2.7	3.1	4.5	3.5	5.6	2.0	0.9	0.7
New York	0.9	2.2	1.8	2.4	2.1	3.2	2.5	2.6	1.2	0.6	0.4	0.3
New York City	0.4	0.1	0.1	0.0	0.1	0.0	0.0	.	.	.	.	.
North Carolina	2.2	1.7	1.3	1.2	0.8	0.9	0.6	0.7	0.3	0.4	0.2	0.3
North Dakota	0.3	0.8	0.6	0.5	0.2	1.1	.	0.6	.	0.2	0.2	.
Ohio	0.9	1.5	0.9	0.3	0.2	0.1	0.3	0.2	0.1	0.0	0.1	0.1
Oklahoma	0.9	1.5	1.5	1.5	1.9	1.7	0.2	0.3	0.7	0.5	0.5	0.2
Oregon	2.1	4.5	2.9	1.8	1.5	1.2	0.3	0.1	0.6	0.7	0.8	0.4
Pennsylvania	0.7	0.4	0.3	0.3	0.4	0.5	0.5	0.7	1.0	0.6	0.4	1.2
Rhode Island	.	1.2	0.7	1.3	2.0	0.8	0.6	0.8	0.4	0.3	0.7	.
South Carolina	0.4	1.1	0.0	0.1	0.3	0.6	0.9	1.1	0.5	0.6	0.1	0.3
South Dakota	0.6	0.1	.	.	.	0.1	.	.	.	.	.	.
Tennessee	3.1	9.7	25.2	19.6	17.3	18.8	7.5	4.5	3.2	2.2	2.0	1.2
Texas	0.9	0.8	1.6	2.3	1.7	1.9	1.1	2.0	2.3	1.8	1.3	2.4
Utah	1.6	1.4	2.0	2.2	0.9	0.7	0.9	0.2	1.0	0.3	0.6	0.1
Vermont	1.4	1.2	3.0	1.0	2.8	2.4	4.4	0.7	1.0	1.2	0.8	1.1
Virginia	0.7	0.6	0.8	0.8	0.4	0.3	0.3	0.4	0.2	0.2	0.0	0.0
Washington	2.9	3.3	3.6	4.2	5.5	4.3	1.2	0.7	0.5	0.4	0.7	0.5
West Virginia	0.2	0.2	0.4	2.4	2.6	2.4	0.5	1.0	0.5	1.2	1.3	1.4
Wisconsin	0.3	2.0	2.0	0.8	.	.	.	0.5	2.8	0.3	.	.
Wyoming	1.1	1.7	14.2	25.4	37.3	46.6	37.3	17.3	21.2	18.3	0.4	1.6

*Page intentionally left blank*



## Acute Hepatitis A, 2001

### Summary

With an average of 28,000 cases per year (range: 23,112-35,821) during 1987-1997, hepatitis A has historically been one of the most frequently reported diseases in the United States. However, effective vaccines to prevent hepatitis A virus (HAV) infection have been available in the U.S. since 1995 for use in individuals at least two years of age. These vaccines have provided the opportunity to substantially reduce disease incidence and potentially eliminate transmission.

Since 1996, hepatitis A vaccine has been recommended for individuals at increased risk of hepatitis A including international travelers, men who have sex with men, and injecting and non-injecting drug users. In 1999, routine vaccination was also recommended for children living in 11 states, ten of which are in the western region, with average hepatitis A rates during 1987-1997 that were at least 20/100,000 and was suggested for children in an additional six states where rates were less than 20/100,000 but above 10/100,000 which was approximately the national average for the time period.

Recent changes in hepatitis A rates highlighted below suggest that these recommendations are having an impact in reducing the transmission of HAV in the U.S. The overall rate in 2001 is the lowest yet recorded. The dramatic decline in rates that has been observed in recent years also has been accompanied by substantial shifts in the epidemiologic profile of this disease in the United States with an increasing proportion of cases occurring among adults, particularly those in high risk groups such as men who have sex with men. Further monitoring of disease rates is needed to determine if the current low rates are sustained and attributable to vaccination and to identify groups and areas where additional vaccination efforts are needed.

- Historically, hepatitis A rates have varied cyclically with periodic nationwide increases. The national rate of hepatitis A has declined steadily since the last peak that occurred in 1995. With 10,615 cases reported for the year 2001, the national incidence of hepatitis A is now the lowest yet recorded (3.8/100,000). *Figure 3*
- In addition to temporal variation, hepatitis A rates have consistently varied geographically with higher rates in the West than elsewhere in the country. Following the 1999 issuance of recommendations for routine childhood vaccination that focused on states with consistently elevated rates of hepatitis A, incidence rates in the West have declined steadily and for the first time are approximately equal to those in other regions of the U.S. *Figure 4 and 5*
- Incidence of hepatitis A varies by age. Since the last nationwide increase, rates have declined among all age groups but the greatest decreases have been among children. Historically, the highest rates have been among children and young adults with the lowest rates observed among persons greater than 40 years of age. However, since 1997, rates among children have declined more rapidly than among adults and in 2001, the highest rates were in persons 25-39 years of age. Although the decline in rates was greatest in children 5-14 years, the lowest rates in 2001 continue to be


among persons <5 years of age and among persons 40+ years. However, asymptomatic infection is common among very young children and reported cases in children <5 represent only a small proportion of infections occurring in this age group. The low and relatively stable rates among persons 40+ years of age reflect the high proportion of persons in this age group with immunity due to a previous infection; data from the Third National Health and Nutrition Examination Survey (NHANES III) conducted during 1988-1994 (CDC, unpublished data) indicated that approximately one third of the U.S. population have serologic evidence of immunity to HAV. *Figure 6*

- In 2001, the rate of hepatitis A among males was 5.4 (per 100,000 persons) vs. 2.9 among females. Rates have historically been higher among males than females but this difference has increased since 1995 and there are now 1.8 male cases for every female case. The rate of hepatitis A is similar in males and females in age groups less than 19 years and in persons greater than 60 but between ages 20-60, males had rates that were 1.5-3.8 times higher than among females with the greatest difference being observed for adults age 30-39. *Figure 7 and 8*
- Historically, hepatitis A rates have differed by race with the highest rates among American Indian/Alaska Natives and the lowest rates among Asians and by ethnicity with higher rates among Hispanics than non-Hispanics. However, rates among American Indians which were greater than 60/100,000 prior to 1995 have decreased dramatically following widespread vaccination in this group and in 2001, are approximately the same as those in other races. Rates among Hispanics have also decreased since 1997 but remain higher than those for Non-Hispanics. *Figure 9*
- Among cases where information about exposures during the incubation period was determined, the most common risk factors for hepatitis A in 2001 were sexual or household contact with another person with hepatitis A, international travel to areas endemic for hepatitis A and male homosexual activity with 12.4%, 10.4% and 9.1% of cases attributed to each of these exposures respectively. The proportion of cases attributed to male homosexual activity increased from 2.3% in 1990 to 3.3% in 1995 to 7.7% in 1998 while the proportion attributed to travel increased from 3.4% in 1990 to 4.8% in 1995 to 6.3% in 1998. In comparison, the proportion of cases attributed to other risk factors declined during the same time period and less than 4% of cases in 2001 were attributed to each of the following risk factors: food- or water-borne outbreaks, being a child or employee in daycare, or illegal drug use. No risk factor was identified for approximately 50% of cases interviewed. *Table 4, Table 5, and Figure 10*
- Among reported hepatitis A cases in 2001, 71% were jaundiced. 22% of cases were hospitalized because of their illness and 0.4% died. The proportion of cases that were jaundiced was highest in persons 15-39 years of age (76%) and lowest among persons older than 60 years (44%). The proportion of cases hospitalized for their hepatitis increased with age from 13% among children <5 years of age to 31% among persons 60 years of age or older. *Table 6*

Figure 3: Incidence of Reported Hepatitis A,  
United States, 1966-2001



**Figure 4: Incidence of Reported Hepatitis A, by Region,  
United States, 1975-2001**



See page 4 for regional categories

Figure 5: Incidence of Reported Hepatitis A, by County,  
United States, 2001






Figure 6: Incidence of Reported Hepatitis A, by Age,  
United States, 1990-2001




**Figure 7: Incidence of Reported Hepatitis A, by Sex,  
United States, 1990-2001**



Note: The bars indicate the rate per 100,000 (the left y-axis) by gender; the line is the ratio (right y-axis) of the incidence rate among males to that among females.


**Figure 8: Incidence of Reported Hepatitis A, by Age and Sex, United States, 2001**



\* A total of 10,615 cases of Hepatitis A were reported. However, rates exclude patients with missing data for age (1.7% of total), and sex (0.9%) of total.



**Figure 9: Incidence of Reported Hepatitis A, by Race and Ethnicity, United States, 1990-2001**



**Table 4: Epidemiologic Characteristics\* of Patients Reported with Hepatitis A, by Age, United States, 2001 (Crude frequency)**

	Age Groups							
	<15 (n=685)		15-39 (n=1834)		40+ yrs (n=1377)		Total (n=3896)	
	N	%	N	%	N	%	N	%
Sexual or household contact with hepatitis A patient	130	19.0	229	12.5	123	8.9	482	12.4
International travel <sup>†</sup>	217	31.7	148	8.1	79	5.7	444	11.4
Homosexual activity (male)	10	1.5	277	15.1	131	9.5	418	10.7
Injection drug use	2	0.3	100	5.5	18	1.3	120	3.1
Child/employee in day-care center	79	11.5	28	1.5	21	1.5	128	3.3
Suspected food- or waterborne outbreak	25	3.6	54	2.9	56	4.1	135	3.5
Contact of day-care child/employee	76	11.1	125	6.8	53	3.8	254	6.5
Other contact with hepatitis A patient	68	9.9	134	7.3	54	3.9	256	6.6
Unknown	239	34.9	945	51.5	919	66.7	2,103	54.0

\*During the 2 to 6 weeks prior to illness

<sup>†</sup>Of cases that reported travel to a region endemic for hepatitis A, 79% traveled to South/Central America, 12% to Asia/South Pacific, 4% to Africa and 6% to the Middle East.

Note 1: A total of 10,615 cases of hepatitis A were reported. This table includes case reports that contained sufficient information to verify the case definition (i.e. laboratory test results, clinical characteristics).

**Table 5: Epidemiologic Characteristics\* of Patients Reported with Hepatitis A, by Age, United States, 2001 (Mutually exclusive risk factor hierarchy)**

	Age Groups							
	<15		15-39 yrs		40+ yrs		Total	
	N	%	N	%	N	%	N	%
Sexual or household contact with hepatitis A patient	130	19.0	229	12.5	123	8.9	482	12.4
International travel <sup>†</sup>	196	28.6	133	7.3	76	5.5	405	10.4
Homosexual activity (male) <sup>‡</sup>	3	0.4	236	12.9	115	8.4	354	9.1
Injection drug use	2	0.3	82	4.5	16	1.2	100	2.6
Child/employee in day-care center	46	6.7	20	1.1	15	1.1	81	2.1
Suspected food- or waterborne outbreak	15	2.2	39	2.1	45	3.3	99	2.5
Contact of day-care child/employee	20	2.9	69	3.8	33	2.4	122	3.1
Other contact with hepatitis A patient	34	5.0	81	4.4	35	2.5	150	3.9
Unknown	239	34.9	945	51.5	919	66.7	2,103	54.0
Total	685	100.0	1,834	100.0	1,377	100.0	3,896	100.0

\*During the 2 to 6 weeks prior to illness


<sup>†</sup>Of cases attributed to travel to a region endemic for hepatitis A, 79% traveled to South/Central America, 12% to Asia/South Pacific, 4% to Africa and 6% to the Middle East.

<sup>‡</sup>Among male cases, 14% were attributed to homosexual behavior and in males 15-39 years of age, 18% of cases were attributed to this risk factor.

Note 1: A total of 10,615 cases of hepatitis A were reported. This table includes case reports that contained sufficient information to verify the case definition (i.e. laboratory test results, clinical characteristics).

Note 2: For persons who reported multiple risk factors for hepatitis A, their source of infection is assigned to their reported risk factor that is highest in the order listed in the table above.

**Figure 10: Trends in Selected Epidemiologic Characteristics among Patients Reported with Hepatitis A, by Year, United States, 1996-2001**



Note: This analysis is based on the assignment of cases to mutually exclusive risk categories with the source of infection for persons reporting more than one risk factor attributed to the reported risk factor that is highest in the table on the previous page.

**Table 6: Clinical Characteristics of Patients Reported with Hepatitis A, By Age, United States, 2001**

	<b>&lt;5 (n=189)</b>		<b>5-14 (n=668)</b>		<b>15-39 (n=2,306)</b>		<b>40-59 (n=1,267)</b>		<b>60+ (n=466)</b>		<b>All (n=4896)</b>	
	N	%	N	%	N	%	N	%	N	%	N	%
Died from hepatitis	1	0.5	2	0.3	2	0.1	5	0.4	8	1.7	18	0.4
Hospitalized for hepatitis	25	13.2	103	15.4	503	21.8	302	23.8	143	30.7	1,076	22.0
Jaundice	109	57.7	512	76.6	1,749	75.8	899	71.0	205	44.0	3,474	71.0

\*A total of 10,615 cases of hepatitis A including 18 deaths were reported. Calculated percentages include patients with non-missing data for age, and for one or more outcomes of interest (i.e. jaundice, hospitalization or death)

*Page intentionally left blank*

## Acute Hepatitis B, 2001

### Summary

During the past decade, a comprehensive strategy was developed and implemented for achieving the elimination of hepatitis B in the United States. The primary elements of this strategy are: the screening of all pregnant women for HBV infection with the provision of post-exposure prophylaxis to infants born to infected women; the routine vaccination of all infants and children <19 years; and the targeted vaccination of individuals at increased risk of hepatitis B including health care workers, dialysis patients, household contacts and sex partners of persons with chronic HBV infection, recipients of certain blood products, persons with a recent history of having had multiple sex partners or a STD, men who have sex with men, and injecting drug users.

As highlighted below, the incidence of hepatitis B has declined dramatically since implementation of the strategy, particularly among the younger age groups covered by the recommendation for routine childhood immunization. However, high rates of disease continue among adults, particularly males 25-39 years of age, and the high proportion of cases occurring among persons in identified risk groups (i.e. injection drug users, men who have sex with men and persons with multiple sex partners) indicate a need to strengthen efforts to reach these populations with vaccine.

- The overall incidence rate of reported cases of acute hepatitis B in 2001 was 2.8/100,000 with 7844 cases reported nationwide. This represents a decline of more than 70% since 1985 when incidence peaked at 11.5/100,000. *Figure 11*
- For the past decade, hepatitis B rates have been similar for all U.S. regions with rates in the West and Southeast only slightly higher than in the Northeast and Midwest. While there is little variability in hepatitis B rates at the regional level, greater heterogeneity can be seen in the hepatitis B rates of individual states with six states having rates greater than 4.0/100,000 (AR, GA, MI, NM, OR, TN) and 13 states with rates <1.0/100,000 persons. Rates in the Northeast have been increasing since 1999. *Figure 12, Figure 13, and Table 3*
- Hepatitis B rates vary by age with the highest rates reported among persons 25-39 years of age (5.1/100,000 persons) and the lowest among persons less than 15 years of age (0.2/100,000). Rates have declined in all age groups with the greatest percent decline since 1990 occurring among children <15 years of age (88%) and young adults 15-24 years of age (81% decline). Although less dramatic than the declines in the younger age groups most of which are covered by the recommendations for routine hepatitis B vaccination, there have also been substantial decreases in the hepatitis B rates among older persons with a 70% and 50% decrease in rates observed for 25-39 year old and 40+ year old categories respectively. *Figure 14*
- As in previous years, the rate of acute hepatitis B in males (3.4/100,000) continues to be higher than in females (1.9/100,000). The ratio of cases occurring among males to those occurring among females has increased slightly but steadily over

the past decade from 1.5 to 1.8. This difference in hepatitis B rates by sex occurs only in persons more than 19 years of age and is greatest in persons more than 35 years of age where the ratio of male/female cases exceeds 2.0. *Figure 15, Figure 16*


- Rates of hepatitis B continue to decline among all racial and ethnic groups. However, rates of hepatitis B remain highest among non-Hispanic blacks (4.3/100,000) and lowest (1.3/100,000) among non-Hispanic whites. *Figure 17*
- Among cases for which information about exposures during the incubation period were determined, 26% of cases were attributed to sexual contact (including 6% sexual contact with a known hepatitis B case, 12% multiple sexual partners, and 8% male homosexual activity). Another 12% of cases were attributed to injection drug use. Receiving hemodialysis or a blood transfusion, both of which were previously major sources of infection, now account for <0.5% of cases (0.2% and 0.4% respectively) as a result of the vaccination of dialysis patients, improvements in infection control and the required screening of donated blood for markers of HBV infection. Similarly, the percentage of cases attributable to occupational exposure to blood is approximately 0.5% following widespread hepatitis B vaccination of health care workers. In contrast, the role of male homosexual behavior as a source for infection has been increasing steadily in recent years from 5.0% of cases in 1990 to 8.2% in 2001. *Table 7, Table 8, Figure 18*
- Among reported hepatitis B cases in 2001, 64% were jaundiced. 26% of cases were hospitalized because of their illness and 1.0% died. The proportion of cases that were jaundiced was approximately 62% in persons 5 years of age or older ranging from 55% among persons 60+ years to 66% among persons 15-39 years of age; less than 15% of cases occurring in children less than 5 years of age presented with jaundice (warning: number of cases in this age group extremely small). The proportion of cases hospitalized for their hepatitis increased with age from 0% among children <5 years of age to 32% among persons 60 years of age or older. *Table 9*



**Figure 11: Incidence of Reported Acute Hepatitis B,  
United States, 1966-2001**




**Figure 12: Incidence of Reported Acute Hepatitis B, by Region, United States, 1975-2001**




See page 4 for regional categories


Figure 13: Incidence of Reported Acute Hepatitis B, by County, United States, 2001



**Figure 14: Incidence of Reported Acute Hepatitis B, by Age, United States, 1990-2001**




**Figure 15: Incidence of Reported Acute Hepatitis B, by Sex, United States, 1990-2001**




Note: The bars indicate the rate per 100,000 (the left y-axis) by gender; the line is the ratio (right y-axis) of the incidence rate among males to that among females

**Figure 16: Incidence of Reported Acute Hepatitis B, by Age and Sex, United States, 2001**



\* A total of 7,944 cases of hepatitis B were reported. Rates exclude patients with missing data for age (1.0% of total) and sex (0.9% of total).

**Figure 17: Incidence of Reported Acute Hepatitis B, by Race and Ethnicity, United States, 1990-2001**



**Table 7: Epidemiologic Characteristics of Patients Reported with Acute Hepatitis B, by Age, United States, 2001 (Crude frequency)**

	Age Groups					
	<40 (n=1403)		40+ yrs (n=834)		Total (n=2237)	
	N	%	N	%	N	%
Injection drug use	213	15.2	56	6.7	269	12.0
Sexual contact with hepatitis B patient	106	7.6	49	5.9	155	6.9
Household contact of hepatitis B patient	19	1.4	18	2.2	37	1.7
Homosexual activity (male)	153	10.9	55	6.6	208	9.3
Medical employee with contact with blood	12	0.9	5	0.6	17	0.8
Hemodialysis	.	.	5	0.6	5	0.2
Multiple sex partners <sup>†</sup>	341	24.3	124	14.9	465	20.8
Blood transfusion	2	0.1	6	0.7	8	0.4
Other <sup>‡</sup>	354	25.2	220	26.4	574	25.7
Unknown	627	44.7	436	52.3	1,063	47.5

<sup>†</sup>More than 1 sex partner in the 6 weeks-6 months prior to illness onset

<sup>‡</sup>Other includes: other (non-household and non-sexual) contact with a hepatitis B patient, dental /oral surgery, other surgery (excluding oral), acupuncture, tattoo, percutaneous injury(e.g. needlestick).

Note 1: A total of 7,844 cases of hepatitis B were reported. However, calculated percentages are based on case reports that included sufficient information to verify the case definition (i.e. laboratory test results, clinical characteristics) and information on age and exposure history.



**Table 8: Epidemiologic Characteristics of Patients Reported with Acute Hepatitis B, by Age, United States, 2001 (mutually exclusive categories)**

	Age Groups					
	<40 yrs		40+ yrs		Total	
	N	%	N	%	N	%
Injection drug use	213	15.2	56	6.7	269	12.0
Sexual contact with hepatitis B patient	88	6.3	47	5.6	135	6.0
Household contact of hepatitis B patient	12	0.9	16	1.9	28	1.3
Homosexual activity (male)*	133	9.5	51	6.1	184	8.2
Medical Employee with contact with blood	7	0.5	5	0.6	12	0.5
Hemodialysis	.	.	4	0.5	4	0.2
Multiple sex partners <sup>†</sup>	185	13.2	79	9.5	264	11.8
Blood transfusion	2	0.1	6	0.7	8	0.4
Other <sup>‡</sup>	136	9.7	134	16.1	270	12.1
Unknown	627	44.7	436	52.3	1,063	47.5
Total	1,403	100.0	834	100.0	2,237	100.0

\*Among male cases, 13% were attributed to homosexual behavior and in males <40 years of age, 15% of cases were attributed to this risk factor.


<sup>†</sup>More than 1 sex partner in the 6 weeks-6 months prior to illness onset

<sup>‡</sup>Other includes: other (non-household and non-sexual) contact with a hepatitis B patient, dental /oral surgery, other surgery (excluding oral), acupuncture, tattoo, percutaneous injury(e.g. needlestick).

Note 1: A total of 7,844 cases of hepatitis B were reported. However, calculated percentages are based on case reports that included sufficient information to verify the case definition (i.e. laboratory test results, clinical characteristics) and information on age and exposure history.

Note 2: For persons who reported multiple risk factors for hepatitis B, their source of infection is assigned to their reported risk factor that is highest in the order listed in the table above.

**Figure 18: Trends in Selected Epidemiologic Characteristics among Patients Reported with Acute Hepatitis B, by Year, United States**



Note: This analysis is based on the assignment of cases to mutually exclusive risk categories with the source of infection for persons reporting more than one risk factor attributed to the reported risk factor that is highest in the table on the previous page.

**Table 9: Clinical Characteristics of Patients Reported with Acute Hepatitis B, by Age, United States, 2001**

	<b>&lt;5 (n=16)</b>		<b>5-14 (n=20)</b>		<b>15-39 (n=2,184)</b>		<b>40-59 (n=1,134)</b>		<b>60+ (n=211)</b>		<b>All (n=3565)</b>	
	N	%	N	%	N	%	N	%	N	%	N	%
Died from hepatitis	0	0.0	0	0.0	17	0.8	12	1.1	8	3.8	37	1.0
Hospitalized for hepatitis	0	0.0	3	15.0	570	26.1	298	26.3	69	32.7	940	26.4
Jaundice	2	12.5	13	65.0	1,445	66.2	704	62.1	115	54.5	2,279	63.9

Note: A total of 7,844 cases of Hepatitis B including 37 deaths were reported. Calculated percentages include case reports with non-missing data for age and for one or more of the outcomes of interest (i.e., jaundice, hospitalization, or death).

*Page intentionally left blank*

## Acute Hepatitis C/NANB Hepatitis, 2001

### Summary

With an estimated 2.7 million chronically infected persons nationwide, hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States. No effective vaccine against this infection is available. National recommendations for prevention and control of HCV infection issued in 1998 rely on primary prevention activities to reduce the risk for HCV transmission. These activities include: screening and testing of blood donors, viral inactivation of plasma-derived products, risk-reduction counseling and services, and implementation and maintenance of infection control practices.

Incidence of hepatitis C has been declining since the late 1980s. This decline is largely the result of a decrease in cases reported among injecting drug users (IDU), the reasons for which are unknown. The majority of hepatitis C cases continue to occur in adult age groups (persons >25 years of age) with injecting drug use the most commonly identified risk factor for infection. Transmission of HCV associated with transfusion, an important risk factor for infection in the past, is now rare. It is expected that the incidence of new infections will continue to decline with ongoing implementation of existing prevention recommendations. However, persons with chronic HCV infection can be a source of infection to others. Vigilance is needed to ensure that any new cases of hepatitis C are identified and investigated to determine the source of infection and limit further spread of the virus.

- 3977 cases of acute hepatitis C/NANB hepatitis were reported in 2001. However, 2337 (60%) of these were reported from only two states (Missouri and New Jersey); these reports were made on the basis of laboratory reports alone and the majority of them represent chronic rather than acute infection. All analyses excluded reports from these two states. Based on the 1640 cases reported by all other states, the overall national rate of reported acute hepatitis C/NANB was 0.6 per 100,000. *Figure 19*
- Historically, because of concerns about the quality of NNDSS data, national trends in hepatitis C/NANB have been monitored using data collected through the Sentinel Counties Study of Viral Hepatitis. However, in recent years, analysis of case reports meeting the definition for acute, symptomatic hepatitis C /NANB collected through NNDSS have yielded similar results to those from the Sentinel Counties Study suggesting that nationally reported cases can more reliably be used to monitor trends incidence and risk factors for acute hepatitis C. *Figure 19*
- Rates have been declining in all age groups since the mid-1990s. The greatest decline in incidence has been among 25-39 year olds which has historically been the age group with the highest rates of disease. In this age group, incidence has declined by 84% since 1992 to 0.9/100,000 in 2001 and is now approximately the same as for persons 40 years or more. Few cases are reported in persons <15 years of age. *Figure 20*

- As in previous years, the rate of hepatitis C in 2001 is higher among males (0.8 per 100,000) than among females (0.4 /100,000). The ratio of cases occurring among males to those occurring among females has remained relatively stable with a range of 1.7-1.9 during the past 5 years. This difference in hepatitis C rates by sex is evident in persons 20 years of age and older. *Figure 21, Figure 22*
- Incidence of hepatitis C/NANB varies by race and ethnicity. Rates have declined in all racial groups since 1995 but non-Hispanic blacks and American Indian/ Alaska Natives continue to have higher incidence rates than other racial/ethnic groups, including non-Hispanic whites. Rates among Hispanics have historically been higher than among non-Hispanic whites (but lower than for non-Hispanic blacks) but in 2000 and 2001 were lower than for any other racial/ethnic group except Asian or Pacific Islanders who continue to have the lowest incidence of hepatitis C/NANB. *Figure 23*
- Among cases for which information about exposures during the incubation period was determined, the most common risk factor for hepatitis C/NANB in 2001 was injection drug use (16.1% of all cases and 21% of cases occurring among persons less than 40 years of age). The proportion of cases attributed to injection drug use has been increasing over the past decade from 6.5% in 1992 to 8.5% in 1995 to 11% in 1998. Another 6.6% of cases were attributed to sexual exposure (3.2% to sexual contact with a known case and 3.4% to a history of multiple sex partners during the incubation period). Less than 1% of cases were attributed to occupational exposure to blood. A history of transfusion or dialysis, both of which were previously important sources of HCV infection now account together for <0.5% of cases. No risk factor was identified for 69% of cases interviewed. *Table 10, Table 11*

**Figure 19: Incidence of Reported Acute Hepatitis C/NANB, United States, 1982-2001**






Figure 20: Incidence of Reported Acute Hepatitis C/NANB, by Age, United States, 1992-2001






**Figure 21: Incidence of Reported Acute Hepatitis C/NANB, by Sex, United States, 1992-2001**




**Figure 22: Incidence of Reported Acute Hepatitis C/NANB, by Age and Sex, United States, 2001**



A total of 1,640 cases of Hepatitis C/NANB were reported, however, rates excluded patients missing data for age and sex.

**Figure 23: Incidence of Reported Acute Hepatitis C/NANB, by Race and Ethnicity, United States, 2001**



**Table 10: Epidemiologic Characteristics of Patients Reported with Acute Hepatitis C/NANB, by Age, United States, 2001 (Crude Frequency)**

	Age Groups					
	<40 yrs (n=211)		40+ yrs (n=229)		Total (n=440)	
	N	%	N	%	N	%
Injection drug use	44	20.9	27	11.8	71	16.1
Employment in medical/dental field	3	1.4	1	0.4	4	0.9
Hemodialysis	.	.	1	0.4	1	0.2
Sexual contact with hepatitis C patient	8	3.8	12	5.2	20	4.5
Household contact of hepatitis C patient	5	2.4	3	1.3	8	1.8
Multiple sex partners <sup>†</sup>	25	11.8	12	5.2	37	8.4
Blood transfusion	.	.	1	0.4	1	0.2
Other contact of hepatitis C patient	8	3.8	5	2.2	13	3.0
Other <sup>‡</sup>	34	16.1	21	9.2	55	12.5
Unknown	129	61.1	173	75.5	302	68.6

<sup>†</sup>More than one sex partner

<sup>‡</sup>Other: Case reported one or more of the following exposures: dental or oral surgery, surgery other than oral surgery, acupuncture, tattooing, or other percutaneous exposure (e.g. needlestick)

Note: A total of 1,640 cases of hepatitis C/NANB were reported. However, calculated percentages are based on case reports that included sufficient information to verify the case definition (i.e. laboratory test results, clinical characteristics) and exposure information.

**Table 11: Epidemiologic Characteristics of Patients Reported with Acute Hepatitis C/NANB by Age, United States, 2001 (Mutually exclusive categories)**

	Age Groups					
	<40 yrs		40+ yrs		Total	
	N	%	N	%	N	%
Injection drug use	44	20.9	27	11.8	71	16.1
Employment in medical/dental field	2	0.9	1	0.4	3	0.7
Hemodialysis	.	.	.	.	.	0.0
Sexual contact with hepatitis C patient	6	2.8	8	3.5	14	3.2
Household contact of hepatitis C patient	3	1.4	2	0.9	5	1.1
Multiple sex partners <sup>†</sup>	9	4.3	6	2.6	15	3.4
Blood transfusion	.	.	1	0.4	1	0.2
Other contact of hepatitis C patient	4	1.9	1	0.4	5	1.1
Other <sup>‡</sup>	14	6.6	10	4.4	24	5.5
Unknown	129	61.1	173	75.5	302	68.6
Total	211	100.0	229	100.0	440	100.0


<sup>†</sup>More than one sex partner

<sup>‡</sup>Other: Case reported one or more of the following exposures: dental or oral surgery, surgery other than oral surgery, acupuncture, tattooing, or other percutaneous exposure (e.g. needlestick)

Note 1: A total of 1,640 cases of hepatitis C/NANB were reported. However, calculated percentages are based on case reports that included sufficient information to verify the case definition (i.e. laboratory test results, clinical characteristics) and exposure information.

Note 2: For persons who reported multiple risk factors for hepatitis C/NANB, their source of infection is assigned to their reported risk factor that is highest in the order listed in the table above.

**Figure 24: Trends in Selected Epidemiologic Characteristics among Patients Reported with Acute Hepatitis C/NANB, by Year**



Note: This analysis is based on the assignment of cases to mutually exclusive risk categories with the source of infection for persons reporting more than one risk factor attributed to the reported risk factor that is highest in the table on the previous page.

**Table 12: Clinical Characteristics of Patients Reported with Acute Hepatitis C/NANB by Age, United States, 2001**

	Age Group									
	5-14 (n=3)		15-39 (n=163)		40-59 (n=177)		60+ (n=15)		Total (n=358)	
	N	%	N	%	N	%	N	%	N	%
Died from hepatitis	0	0.0	0	0.0	2	1.1	0	0.0	2	0.6
Hospitalized for hepatitis	1	33.3	41	25.2	36	20.3	4	26.7	82	22.9
Jaundice	0	0.0	89	54.6	58	32.8	6	40.0	153	42.7

Note: A total of 1,640 cases of Hepatitis C/NANB were reported. Calculated percentages include patients with non-missing data for age and for one or more of the outcomes of interest (i.e., jaundice, hospitalization, and death).

*Page intentionally left blank*



## Future Directions

### Surveillance for acute viral hepatitis

#### *Hepatitis A*

Continued monitoring of national and state-specific incidence rates is needed to determine if the dramatic decline in rates that has occurred following introduction of hepatitis A vaccines in this country is sustained and attributable to vaccination.

#### *Hepatitis B*

The analysis of surveillance data will continue to provide critical information to assess the impact of the national strategy for eliminating hepatitis B in the United States. With ongoing vaccination of infants and children, it is expected that the number of cases occurring in young age groups will continue to decline. Enhanced investigation of cases reported in children and other groups for which vaccination is recommended (e.g. health care workers, men who have sex with men) is needed to determine if and why these individuals were not vaccinated so that additional cases can be prevented. In addition, the investigation of cases occurring in risk groups can identify settings in which these individuals might be reached with vaccine. The investigation of new cases identified in older persons or others who do not have typical risk factors (e.g., multiple sex partners, recent IDU) for HBV should be done to identify outbreaks associated with health care or other unusual settings.

#### *Hepatitis C/NANB*

The incidence of acute hepatitis C continues to decline and outbreaks are rare. However, the investigation of any new infection is needed to identify and control ongoing sources of transmission. In particular, investigation of new cases occurring in persons who do not have typical risk factors (e.g., recent IDU) for HCV infection is needed to identify outbreaks associated with health care or other unusual settings. Case investigation efforts should be focused on the investigation of cases of acute disease or documented cases of seroconversion. The investigation of all persons testing positive for anti-HCV is not recommended because the large number of anti-HCV positive reports requiring investigation would rapidly overwhelm health department resources and most anti-HCV positive persons are chronically rather than acutely infected. However, if resources are available, expanding investigation efforts to include follow-up of reports of anti-HCV positive individuals who are more likely to have recent infections (e.g. persons <30 years of age) should be considered as an additional way to identify new HCV infections.

### Surveillance for perinatal HBV infection

Reporting of perinatal HBV infection through NETSS began in 2001. Seven states reported one or more cases through NNDSS with a total of 30 cases reported for the year. However, not all states have begun reporting through this mechanism. Based on

estimations made using other data sources, approximately 1000 infants were infected with HBV in 2001 of whom 80% will remain chronically infected. Once reporting mechanisms are stabilized, analysis of reported cases will be included as part of this report.

## **Surveillance for chronic hepatitis virus infections**

To date, national surveillance has been conducted for cases of acute disease only. However, in June 2002, the Council of State and Territorial Epidemiologists voted to include chronic HBV infection and HCV infection (past or present) in the list of nationally notifiable diseases and approved a case definition for each of these conditions. Since January 2003, 15 states have begun reporting these cases electronically through NETSS to CDC. The approved case definitions for chronic HBV infection and HCV infection (past or present) are available at [www.cdc.gov/epo/dphsi/casedef/](http://www.cdc.gov/epo/dphsi/casedef/). The identification and reporting of chronically infected persons is needed to facilitate follow-up of these individuals to ensure that they are receiving appropriate interventions including counseling and referral for medical evaluation. In addition, it will allow states to determine the characteristics of persons being identified with chronic infection and provide data that can be used to describe the local burden of disease due to HBV and HCV infection.

## **NEDSS and new case report forms**

Over the next several years, implementation of a new unified disease reporting system called the National Electronic Disease Surveillance System (NEDSS) is expected. This system will replace the currently used NETSS (National Electronic Telecommunication System for Surveillance). As part of this new system, new forms for investigating and reporting cases of viral hepatitis will be introduced. In contrast to the single form that is currently used (Form 53.1) for reporting all types of viral hepatitis, the new system will use case investigation forms that have been developed for each type of reportable hepatitis. In contrast to the NETSS system which is designed to report events, the NEDSS system has a patient based structure which means that it will be possible to link multiple disease reports for an individual. This type of system has the potential to enhance capacity to do surveillance for viral hepatitis because it allows the tracking of individuals who have been previously identified as having hepatitis virus infections and may allow linkage with other information (reports of other diseases, hospital data, clinical test results) useful for investigating and evaluating potential cases of viral hepatitis.

## Appendices

### Appendix I: State and Territorial Epidemiologists and Laboratory Directors

State and Territorial Epidemiologists and Laboratory Directors are acknowledged for their contributions to hepatitis surveillance programs. The epidemiologists and the laboratory directors listed below were in the positions shown as of July 2003.

State/Territory	State Epidemiologist	State Laboratory Director
Alabama	Charles Woernle	William J Callan
Alaska	John Middaugh	Bernard Jilly
Arizona	Bob England	Wesley Press
Arkansas	Frank Wilson	Michael Loeffelholz
California	Gilberto Chavez	Paul Kimsey
Colorado	Ned Calonge	David Butcher
Connecticut	James Hadler	Katherine Kelley
Delaware	A. LeRoy Hathcock	Jane Getchell
District of Columbia	John Davies-Cole	Maurice Knuckles
Florida	Landis Crocket	Ming S Chan
Georgia	Paul Blake	Elizabeth Franko
Hawaii	Paul Effler	Vernon Miyamoto
Idaho	Christine Hahn	Richard Hudson
Illinois	Mark Dworkin	David Maserang
Indiana	Robert Teclaw	David Nauth
Iowa	Patricia Quinlisk	Mary Gilchrist
Kansas	Gianfranco Pezzino	Duane Boline
Kentucky	Steven Englender	George Graham
Louisiana	Raoult Ratard	Henry Bradford Jr.
Maine	Kathleen Gensheimer	John Krueger
Maryland	David Blythe	Jack Deboy
Massachusetts	Alfred Demaria Jr.	Ralph Timperi
Michigan	Matthew Boulton	Francis P Downes
Minnesota	Harry Hull	Norman Crouch
Mississippi	Mary Currier	Joe Graves
Missouri	Joseph Malone	Eric Blank
Montana	Todd Damrow	Michael Spence
Nebraska	Thomas Safranek	Steve H Hinrichs
Nevada	Randall Todd	L. Dee Brown
New Hampshire	Jesse Greenblatt	Veronica C Malmberg
New Jersey	Eddy A Bresnitz	Dennis Flynn
New Mexico	C. Mack Sewell	David E Mills
New York City	Marci Layton	
New York State	Perry Smith	Lawrence Sturman
North Carolina	Jeff Engel	Lou F Turner
North Dakota	Larry Shireley	Bonna Cunningham
Ohio	Forrest Smith	William Becker
Oklahoma	Michael Crutcher	John J Mathewson
Oregon	Melvin Kohn	Michael Skeels
Pennsylvania	James Rankin	Bruce Kleger
Rhode Island	Utpala Bandy	Gregory Hayes
South Carolina	James J. Gibson	Harold Dowda
South Dakota	Lon Kightlinger	Michael Smith
Tennessee	Allen Craig	Michael W Kimberly
Texas	Dennis Perrotta	Susan Neill
Utah	Albert Rolfs	Charles Brokopp
Vermont	Susan E Schoenfeld	Mary Celotti
Virginia	John Marr	James L Pearson
Washington	Jo Hofmann	Romesh Gautom
West Virginia	Loretta Haddy	Andrea Labik
Wisconsin	Jeffrey Davis	Ronald H Laessig
Wyoming	Karl Musgrave	Richard Harris
American Samoa	Joseph Tufa	Joseph Tufa
Federated States of Micronesia	Jean-Paul Quez	
Guam	Robert Haddock	Peter John Camacho
Marshall Islands	Tom Kijiner	
Northern Mariana Island	Jose Chong	Joseph Villagomez
Puerto Rico	Angeles Rodriguez	Jose L Molinaris
Virgin Islands	Mavis Matthew	Norbert Mantor

*Page intentionally left blank*

# HEPATITIS SURVEILLANCE — NUMBER 58

## Appendix II: Viral Hepatitis Case Report Form

<b>VIRAL HEPATITIS CASE RECORD</b> <b>FOR REPORTING OF PATIENTS WITH SYMPTOMATIC ACUTE VIRAL HEPATITIS</b> <b>(SEE CASE DEFINITION ON REVERSE)</b>													
<b>STATE GEOGRAPHIC CODE</b> (1) (2) (3) (4) (5) STATE CASE NO. (6) (7) (8) (9) (10) (11)				<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b> <b>PUBLIC HEALTH SERVICE</b> Centers for Disease Control and Prevention Hepatitis Branch, (G37) Atlanta, Georgia 30333				<b>CDC CASE NO.</b> (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) (111) (112) (113) (114) (115) (116) (117) (118) (119) (120) (121) (122) (123) (124) (125) (126) (127) (128) (129) (130) (131) (132) (133) (134) (135) (136) (137) (138) (139) (140) (141) (142) (143) (144) (145) (146) (147) (148) (149) (150) (151) (152) (153) (154) (155) (156) (157) (158) (159) (160) (161) (162) (163) (164) (165) (166) (167) (168) (169) (170) (171) (172) (173) (174) (175) (176) (177) (178) (179) (180) (181) (182) (183) (184) (185) (186) (187) (188) (189) (190) (191) (192) (193) (194) (195) (196) (197) (198) (199) (200) (201) (202) (203) (204) (205) (206) (207) (208) (209) (210) (211) (212) (213) (214) (215) (216) (217) (218) (219) (220) (221) (222) (223) (224) (225) (226) (227) (228) (229) (230) (231) (232) (233) (234) (235) (236) (237) (238) (239) (240) (241) (242) (243) (244) (245) (246) (247) (248) (249) (250) (251) (252) (253) (254) (255) (256) (257) (258) (259) (260) (261) (262) (263) (264) (265) (266) (267) (268) (269) (270) (271) (272) (273) (274) (275) (276) (277) (278) (279) (280) (281) (282) (283) (284) (285) (286) (287) (288) (289) (290) (291) (292) (293) (294) (295) (296) (297) (298) (299) (300) (301) (302) (303) (304) (305) (306) (307) (308) (309) (310) (311) (312) (313) (314) (315) (316) (317) (318) (319) (320) (321) (322) (323) (324) (325) (326) (327) (328) (329) (330) (331) (332) (333) (334) (335) (336) (337) (338) (339) (340) (341) (342) (343) (344) (345) (346) (347) (348) (349) (350) (351) (352) (353) (354) (355) (356) (357) (358) (359) (360) (361) (362) (363) (364) (365) (366) (367) (368) (369) (370) (371) (372) (373) (374) (375) (376) (377) (378) (379) (380) (381) (382) (383) (384) (385) (386) (387) (388) (389) (390) (391) (392) (393) (394) (395) (396) (397) (398) (399) (400) (401) (402) (403) (404) (405) (406) (407) (408) (409) (410) (411) (412) (413) (414) (415) (416) (417) (418) (419) (420) (421) (422) (423) (424) (425) (426) (427) (428) (429) (430) (431) (432) (433) (434) (435) (436) (437) (438) (439) (440) (441) (442) (443) (444) (445) (446) (447) (448) (449) (450) (451) (452) (453) (454) (455) (456) (457) (458) (459) (460) (461) (462) (463) (464) (465) (466) (467) (468) (469) (470) (471) (472) (473) (474) (475) (476) (477) (478) (479) (480) (481) (482) (483) (484) (485) (486) (487) (488) (489) (490) (491) (492) (493) (494) (495) (496) (497) (498) (499) (500) (501) (502) (503) (504) (505) (506) (507) (508) (509) (510) (511) (512) (513) (514) (515) (516) (517) (518) (519) (520) (521) (522) (523) (524) (525) (526) (527) (528) (529) (530) (531) (532) (533) (534) (535) (536) (537) (538) (539) (540) (541) (542) (543) (544) (545) (546) (547) (548) (549) (550) (551) (552) (553) (554) (555) (556) (557) (558) (559) (560) (561) (562) (563) (564) (565) (566) (567) (568) (569) (570) (571) (572) (573) (574) (575) (576) (577) (578) (579) (580) (581) (582) (583) (584) (585) (586) (587) (588) (589) (590) (591) (592) (593) (594) (595) (596) (597) (598) (599) (600) (601) (602) (603) (604) (605) (606) (607) (608) (609) (610) (611) (612) (613) (614) (615) (616) (617) (618) (619) (620) (621) (622) (623) (624) (625) (626) (627) (628) (629) (630) (631) (632) (633) (634) (635) (636) (637) (638) (639) (640) (641) (642) (643) (644) (645) (646) (647) (648) (649) (650) (651) (652) (653) (654) (655) (656) (657) (658) (659) (660) (661) (662) (663) (664) (665) (666) (667) (668) (669) (670) (671) (672) (673) (674) (675) (676) (677) (678) (679) (680) (681) (682) (683) (684) (685) (686) (687) (688) (689) (690) (691) (692) (693) (694) (695) (696) (697) (698) (699) (700) (701) (702) (703) (704) (705) (706) (707) (708) (709) (710) (711) (712) (713) (714) (715) (716) (717) (718) (719) (720) (721) (722) (723) (724) (725) (726) (727) (728) (729) (730) (731) (732) (733) (734) (735) (736) (737) (738) (739) (740) (741) (742) (743) (744) (745) (746) (747) (748) (749) (750) (751) (752) (753) (754) (755) (756) (757) (758) (759) (760) (761) (762) (763) (764) (765) (766) (767) (768) (769) (770) (771) (772) (773) (774) (775) (776) (777) (778) (779) (780) (781) (782) (783) (784) (785) (786) (787) (788) (789) (790) (791) (792) (793) (794) (795) (796) (797) (798) (799) (800) (801) (802) (803) (804) (805) (806) (807) (808) (809) (810) (811) (812) (813) (814) (815) (816) (817) (818) (819) (820) (821) (822) (823) (824) (825) (826) (827) (828) (829) (830) (831) (832) (833) (834) (835) (836) (837) (838) (839) (840) (841) (842) (843) (844) (845) (846) (847) (848) (849) (850) (851) (852) (853) (854) (855) (856) (857) (858) (859) (860) (861) (862) (863) (864) (865) (866) (867) (868) (869) (870) (871) (872) (873) (874) (875) (876) (877) (878) (879) (880) (881) (882) (883) (884) (885) (886) (887) (888) (889) (890) (891) (892) (893) (894) (895) (896) (897) (898) (899) (900) (901) (902) (903) (904) (905) (906) (907) (908) (909) (910) (911) (912) (913) (914) (915) (916) (917) (918) (919) (920) (921) (922) (923) (924) (925) (926) (927) (928) (929) (930) (931) (932) (933) (934) (935) (936) (937) (938) (939) (940) (941) (942) (943) (944) (945) (946) (947) (948) (949) (950) (951) (952) (953) (954) (955) (956) (957) (958) (959) (960) (961) (962) (963) (964) (965) (966) (967) (968) (969) (970) (971) (972) (973) (974) (975) (976) (977) (978) (979) (980) (981) (982) (983) (984) (985) (986) (987) (988) (989) (990) (991) (992) (993) (994) (995) (996) (997) (998) (999) (1000)					
PATIENT'S LAST NAME (please print clearly) (12-26)				FIRST AND MIDDLE NAME (or initials)				OCCUPATION					
STREET ADDRESS				TOWN OR CITY				STATE (Zip Code)				COUNTY (27-36)	COUNTY FIPS CODE (37-40)
AGE (yrs) (41-42) 00 = < 1yr 99 = Unk		DATE OF BIRTH (43-48) Mo / Day / Yr		SEX (49) 1 <input type="checkbox"/> Male 2 <input type="checkbox"/> Female 9 <input type="checkbox"/> Unk		RACE (50) 1 <input type="checkbox"/> American Indian or Alaskan Native 2 <input type="checkbox"/> Asian or Pacific Islander 3 <input type="checkbox"/> Black 5 <input type="checkbox"/> White 9 <input type="checkbox"/> Unk		ETHNICITY (51) 1 <input type="checkbox"/> Hispanic 2 <input type="checkbox"/> Non-Hispanic 9 <input type="checkbox"/> Unk		Reporting physician's diagnosis (52-53) 1 <input type="checkbox"/> Hepatitis A 2 <input type="checkbox"/> Hepatitis B 3 <input type="checkbox"/> Non-A, Non-B 4 <input type="checkbox"/> Hepatitis D 5 <input type="checkbox"/> Hepatitis (Delta) Unspecified			
DO NOT REPORT CASES OF CHRONIC HEPATITIS OR CHRONIC CARRIERS!!													
CLINICAL DATA						LABORATORY RESULTS							
Date of first symptom (54-59) Mo / Day / Yr						IgM Hepatitis A antibody (IgM anti-HAV) (69) 1 <input type="checkbox"/> Pos 2 <input type="checkbox"/> Neg 9 <input type="checkbox"/> Not Tested/Unk							
Date of diagnosis (60-65) Mo / Day / Yr						Hepatitis B surface antigen (HBsAg) (70) 1 <input type="checkbox"/> Pos 2 <input type="checkbox"/> Neg 9 <input type="checkbox"/> Not Tested/Unk							
Was the patient jaundiced? (66) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No						IgM Hepatitis B core antibody (IgM anti-HBc) (71) 1 <input type="checkbox"/> Pos 2 <input type="checkbox"/> Neg 9 <input type="checkbox"/> Not Tested/Unk							
Was the patient hospitalized for hepatitis? (67) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No						Antibody to Delta (anti-HDV) (72) 1 <input type="checkbox"/> Pos 2 <input type="checkbox"/> Neg 9 <input type="checkbox"/> Not Tested/Unk							
Did the patient die from hepatitis? (68) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No													
For purposes of National Surveillance, ASK ALL OF THE FOLLOWING QUESTIONS FOR EVERY CASE OF HEPATITIS. These questions may help determine where the patient acquired his/her infection. Please refer to the work sheet on the back of the last page for additional questions.													
During the <u>2-6 weeks</u> prior to illness													
1. was the patient a child or employee in a nursery, day care center, or preschool? (73) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
2. was the patient a household contact of a child or employee in a nursery, day care center, or preschool? (74) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
3. was the patient a contact of a confirmed or suspected hepatitis A case? (75) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, type of contact: (76) 1 <input type="checkbox"/> Sexual 2 <input type="checkbox"/> Household (non-sexual) 3 <input type="checkbox"/> Other													
4. was the patient employed as a food handler? (77) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
5. did the patient eat raw shellfish? (78) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
6. was the patient suspected as being part of a common-source foodborne or waterborne outbreak? (79) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
7. did the patient travel outside of the U.S. or Canada? (80) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, where: (81) 1 <input type="checkbox"/> So./Central America (including Mexico) 2 <input type="checkbox"/> Africa 3 <input type="checkbox"/> Caribbean 4 <input type="checkbox"/> Middle East													
5 <input type="checkbox"/> Asia/So. Pacific 6 <input type="checkbox"/> Australia/New Zealand 7 <input type="checkbox"/> Other													
Duration of stay: (82) 1 <input type="checkbox"/> 1-3 Days 2 <input type="checkbox"/> 4-7 Days 3 <input type="checkbox"/> More than 7 Days													
During the <u>6 weeks-6 months</u> prior to illness													
8. was the patient a contact of a confirmed or suspected acute or chronic hepatitis B or non-A, non-B case? (83) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, type of contact: (84) 1 <input type="checkbox"/> Sexual 2 <input type="checkbox"/> Household (non-sexual) 3 <input type="checkbox"/> Other													
9. was the patient employed in a medical, dental or other field involving contact with human blood? (85) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, degree of blood contact: (86) 1 <input type="checkbox"/> Frequent (several times weekly) 2 <input type="checkbox"/> Infrequent													
10. did the patient receive blood or blood products (transfusion)? (87) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, specify date(s) received: (88-93) From ___/___/___ to ___/___/___ (94-99)													
11. was the patient associated with a dialysis or kidney transplant unit? (100) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, (101) 1 <input type="checkbox"/> Patient 2 <input type="checkbox"/> Employee 3 <input type="checkbox"/> Contact of patient or employee													
12. did the patient use needles for injection of street drugs? (102) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
13. what was the patient's sexual preference? (103) 1 <input type="checkbox"/> Heterosexual 2 <input type="checkbox"/> Homosexual 3 <input type="checkbox"/> Bisexual 9 <input type="checkbox"/> Unk													
14. how many different sexual partners did the patient have? (104) 1 <input type="checkbox"/> None 2 <input type="checkbox"/> One 3 <input type="checkbox"/> 2-5 4 <input type="checkbox"/> More than 5 9 <input type="checkbox"/> Unk													
15. did the patient have													
dental work or oral surgery? (105) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk						tattooing? (108) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk							
other surgery? (106) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk						an accidental stick or puncture with a needle							
acupuncture? (107) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk						or other object contaminated with blood? (109) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk							
Has this patient ever received the three dose series of Hepatitis B vaccine? (110) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, what year? (111-112) ___ AND was the patient tested for antibody within 1-6 months after the last dose? (113) 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> No 9 <input type="checkbox"/> Unk													
If yes, was the antibody test: (114) 1 <input type="checkbox"/> Pos 2 <input type="checkbox"/> Neg 3 <input type="checkbox"/> Unknown													
Comments:						Investigator's Name							
						Date							

CDC 53.1 Rev. 6-93

This questionnaire is authorized by law (Public Health Service Act, 42 USC 241). Although response to the questions is voluntary, cooperation of the patient is necessary for the study and control of the disease. Public burden for this collection of information is estimated to average 25 minutes per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to PHS Reports Clearance Officer, ATTN: PRA, Hubert H. Humphrey Bldg, Rm 721-H, 200 Independence Ave. SW, Washington, DC 20201, and to the Office of Management and Budget, Paperwork Reduction Project (0920-0009), Washington, DC 20503.

Form Approved  
OMB No. 0920-0009

# HEPATITIS SURVEILLANCE — NUMBER 58

## WORK SHEET

### CASE DEFINITION FOR REPORTING OF ACUTE VIRAL HEPATITIS

Illness with: 1) discrete onset of symptoms and  
2) jaundice or elevated serum aminotransferase levels.

**Hepatitis A:** IgM anti-HAV positive.

**Hepatitis B:** IgM anti-HBc positive if done or HBsAg positive and IgM anti-HAV negative if done.

**Non-A, Non-B Hepatitis:** 1) IgM anti-HAV negative, and  
2) IgM anti-HBc negative if done or HBsAg negative, and  
3) serum aminotransferase levels greater than 2 1/2 times the upper limit of normal.

**Delta Hepatitis:** 1) HBsAg or IgM anti-HBc positive and  
2) Anti-HDV positive.

### FOR USE BY LOCAL HEALTH DEPARTMENTS TO DETERMINE THE PATIENT'S MOST PROBABLE SOURCE OF INFECTION

Patient's name \_\_\_\_\_ Home phone \_\_\_\_\_ Employed by \_\_\_\_\_ Work phone \_\_\_\_\_  
Reporting physician's name, address, and phone # \_\_\_\_\_

If patient was hospitalized for hepatitis, give name of hospital \_\_\_\_\_  
Results of liver function tests: SGOT (AST) \_\_\_\_\_ SGPT (ALT) \_\_\_\_\_ Bilirubin \_\_\_\_\_

### FURTHER INFORMATION FOR ADMITTED RISK FACTORS AND SOURCES LISTED ON FRONT PAGE

IF APPLICABLE:

1. Name, address, and phone # of child care center \_\_\_\_\_
2. Name and address of school, grade, classroom attended \_\_\_\_\_
3. Name, address, and phone # of restaurant where food handler worked (HEPATITIS A ONLY) \_\_\_\_\_
4. Food history of patient for the 2-6 wks prior to onset: (HEPATITIS A ONLY)
  - a. name and location of restaurants \_\_\_\_\_
  - b. name and location of food stores \_\_\_\_\_
  - c. name and location of bakery \_\_\_\_\_
  - d. group meals attended (e.g., reception, church, meeting, etc.) \_\_\_\_\_
  - e. location raw shellfish purchased \_\_\_\_\_
5. Name, address, and phone # of known hepatitis A or hepatitis B contact \_\_\_\_\_ Relationship \_\_\_\_\_

### 6. CONTACTS REQUIRING PROPHYLAXIS FOR HEPATITIS A OR HEPATITIS B

Name	Age	Relationship to case	IG	HBIG	Vaccine

7. If transfused, NOTIFY BLOOD CENTER! Name of blood center \_\_\_\_\_
  - a. number of units of whole blood, packed RBC or frozen RBC received \_\_\_\_\_
  - b. specify type of blood product (e.g., albumin, fibrinogen, factor VIII, etc.) \_\_\_\_\_
8. IF DONOR, name, address, and phone # of donor or plasmapheresis center \_\_\_\_\_ Date \_\_\_\_\_
9. Name, address, and phone # of dialysis center \_\_\_\_\_
10. Name, address, and phone # of dentist or oral surgeon \_\_\_\_\_
11. If other surgery performed, name, address, and phone # of location \_\_\_\_\_
12. Name, address, and phone # of acupuncturist or tattoo parlor \_\_\_\_\_
13. Is patient currently pregnant? \_\_\_\_\_ If yes, give obstetrician's name, address and phone # \_\_\_\_\_
  - a. estimated date and location of delivery \_\_\_\_\_

Comments: \_\_\_\_\_

Investigator's Name and Title \_\_\_\_\_ Date of Interview \_\_\_\_\_

CDC 53.1 Work sheet REV. 6-93

Work sheet

1st Copy — Local Health Department

2nd Copy — Centers for Disease Control

3rd Copy — State Health Department

## **References**

- <sup>1</sup>CDC. Prevention of hepatitis A through active or passive immunization. MMWR 1996; 45(RR:15)
- <sup>2</sup>CDC. Prevention of hepatitis A through active or passive immunization. MMWR 1999; 48(RR:12)
- <sup>3</sup>CDC. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991; 40(RR:13)
- <sup>4</sup>Alter, MJ et al. The prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999; 341:556-62.
- <sup>5</sup>CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(RR:19)
- <sup>6</sup>U.S. Department of Health and Human Services. Healthy People 2010. 2nd ed. (Washington, DC: U.S. Government Printing Office, November 2000)